Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice. Issue 10 (15th May 2017)

• Record Type: Journal Article
• Authors: Roecker, Anthony J.; Egbertson, Melissa; Jones, Kristen L.G.; Gomez, Robert; Kraus, Richard L.; Li, Yuxing; Koser, Amy Jo; Urban, Mark O.; Klein, Rebecca; Clements, Michelle; Panigel, Jacqueline; Daley, Christopher; Wang, Jixin; Finger, Eleftheria N.; Majercak, John; Santarelli, Vincent; Gregan, Irene; Cato, Matthew; Filzen, Tracey; Jovanovska, Aneta; Wang, Ying-Hong; Wang, Deping; Joyce, Leo A.; Sherer, Edward C.; Peng, Xuanjia; Wang, Xiu; Sun, Haiyan; Coleman, Paul J.; Houghton, Andrea K.; Layton, Mark E.
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 27:Issue 10(2017)
• Page Start: 2087
• Page End: 2093
• Publication Date: 2017-05-15
• Subjects: Nav1.7 -- Ion channel -- Pain -- Arylsulfonamide -- Selectivity; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2017.03.085
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: The voltage-gated sodium channel Nav 1.7 is a genetically validated target for the treatment of pain with gain-of-function mutations in man eliciting a variety of painful disorders and loss-of-function mutations affording insensitivity to pain. Unfortunately, drugs thought to garner efficacy via Nav 1 inhibition have undesirable side effect profiles due to their lack of selectivity over channel isoforms. Herein we report the discovery of a novel series of orally bioavailable arylsulfonamide Nav 1.7 inhibitors with high levels of selectivity over Nav 1.5, the Nav isoform responsible for cardiovascular side effects, through judicious use of parallel medicinal chemistry and physicochemical property optimization. This effort produced inhibitors such as compound5 with excellent potency, selectivity, behavioral efficacy in a rodent pain model, and efficacy in a mouse itch model suggestive of target modulation.